Editorial & Opinion
Availability of drugs for severe COVID-19 in sub-Saharan Africa.
العنوان: | Availability of drugs for severe COVID-19 in sub-Saharan Africa. |
---|---|
المؤلفون: | Njonnou SRS; Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.; The University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19*), Dschang, Cameroon., Ouankou CN; Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.; The University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19*), Dschang, Cameroon.; Department of Internal Medicine and Specialties, Yaoundé University Teaching Hospital, Yaoundé, Cameroon., Lekpa FK; Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.; The University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19*), Dschang, Cameroon.; Department of Internal Medicine, Douala General Hospital, Douala, Cameroon., Balti EV; Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.; The University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19*), Dschang, Cameroon.; Diabetes Research Center and Department of Internal Medicine, Universiteit Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium., Choukem SP; Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.; The University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19*), Dschang, Cameroon.; Health and Human Development (2HD) Research Network, Douala, Cameroon. |
المصدر: | The Pan African medical journal [Pan Afr Med J] 2020 May 26; Vol. 35 (Suppl 2), pp. 48. Date of Electronic Publication: 2020 May 26 (Print Publication: 2020). |
نوع المنشور: | Letter |
اللغة: | English |
بيانات الدورية: | Publisher: African Field Epidemiology Network Country of Publication: Uganda NLM ID: 101517926 Publication Model: eCollection Cited Medium: Internet ISSN: 1937-8688 (Electronic) NLM ISO Abbreviation: Pan Afr Med J Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Kampala, Uganda : African Field Epidemiology Network |
مواضيع طبية MeSH: | COVID-19 Drug Treatment*, Receptors, Interleukin-6/*immunology, Africa South of the Sahara ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/pharmacology ; COVID-19/physiopathology ; Humans ; Severity of Illness Index |
مستخلص: | Competing Interests: The author declares no competing interests. |
References: | Front Pharmacol. 2018 Sep 20;9:1070. (PMID: 30294275) Autoimmun Rev. 2020 Jul;19(7):102568. (PMID: 32376398) N Engl J Med. 2020 Sep 3;383(10):994. (PMID: 32649078) BMJ. 2020 May 14;369:m1844. (PMID: 32409486) Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. (PMID: 32350134) JAMA. 2020 May 12;323(18):1824-1836. (PMID: 32282022) Int J Antimicrob Agents. 2020 Jul;56(1):105949. (PMID: 32205204) Health Aff (Millwood). 2015 Mar;34(3):519-27. (PMID: 25715657) N Engl J Med. 2020 May 7;382(19):1787-1799. (PMID: 32187464) J Clin Invest. 2020 Jun 1;130(6):2757-2765. (PMID: 32254064) |
فهرسة مساهمة: | Keywords: COVID-19; drug availability; effective treatment; severe |
المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) 0 (Receptors, Interleukin-6) I031V2H011 (tocilizumab) |
تواريخ الأحداث: | Date Created: 20210224 Date Completed: 20210309 Latest Revision: 20240806 |
رمز التحديث: | 20240806 |
مُعرف محوري في PubMed: | PMC7875718 |
DOI: | 10.11604/pamj.supp.2020.35.2.23698 |
PMID: | 33623573 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1937-8688 |
---|---|
DOI: | 10.11604/pamj.supp.2020.35.2.23698 |